TICKERNERD
Menu
ELMDELMDHealthcare · Medical Devices

ELMD Stock Forecast: Electromed, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$27
+2.25% on the day

The 2 Wall Street analysts covering Electromed, Inc. hold a median 12-month price target of $49 — +78.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$228.0M
Ticker Nerd rank
94 / 100
Median analyst target
$49
Analysts covering
2
Revenue$19.4M+11.6% y/y
Operating income$3.8M
Net income$3.4M
Free cash flow$2.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.3%
1M
−35.7%
YTD
−6.4%
1Y
+8.7%
From 52W high
−41.2%
From 52W low
+17.7%
$23
$46
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ELMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Electromed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Value
87
Growth
83
Volatility
78
Issuance
76
Momentum
68
Size
66
Revisions
60
Accruals
26

Quality (99): The business earns solid, repeatable profits on what it owns.

Accruals (26): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ELMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35$40$45$50$55Oct 25Jan 26Apr 26Jul 26ELMDHigh $50Median $49Low $47

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $47Median $49High $50

The green dot is the last close — the median target sits +78.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Aug 2026Lake StreetMaintainsBuy—
13 May 2026B. Riley SecuritiesMaintainsBuy—
12 Feb 2026Freedom BrokerMaintainsBuy—
19 Nov 2025Freedom BrokerMaintainsBuy—
13 Nov 2025Roth CapitalReiteratesBuy—
27 Aug 2025Lake StreetAssumesBuy$36
27 Aug 2025Roth CapitalMaintainsBuy—
22 July 2025Roth CapitalInitiatesBuy—
20 Feb 2025B. Riley SecuritiesInitiatesBuy—
11 May 2023EF HuttonReiteratesBuy—
16 Feb 2023EF HuttonMaintainsBuy—
15 Feb 2023Lake StreetMaintainsBuy—
28 Dec 2022Lake StreetAssumesBuy$20
6 Sept 2022EF HuttonInitiatesBuy—
5 Aug 2022Lake StreetInitiatesBuy—
24 Nov 2020Northland Capital MarketsInitiatesOutperform—
18 Oct 2019Dougherty & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ELMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Electromed, Inc. returned +8.7% against +17.5% for the S&P 500, dividends included.

ELMD vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Oct 25Jan 26Apr 26Jul 26ELMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ELMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1.7%
Analysts raising
0
Analysts cutting
1
Fundamentals

Electromed, Inc. (ELMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
21.0×

Cheaper than 36% of US stocks

Price / sales
3.1×

Cheaper than 40% of US stocks

Price / book
4.2×

Cheaper than 24% of US stocks

EV / EBITDA
14.0×

Cheaper than 25% of US stocks

Growth & margins
Revenue growth (YoY)
11.6%

Higher than 56% of US stocks

Earnings growth (YoY)
54.3%

Higher than 76% of US stocks

Gross margin
78.7%

Higher than 90% of US stocks

Operating margin
19.7%

Higher than 79% of US stocks

Net margin
15.3%

Higher than 78% of US stocks

Returns & dividend
Return on equity
23.3%

Higher than 84% of US stocks

Return on assets
14.5%

Higher than 97% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Electromed, Inc. (ELMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Electromed, Inc. has a market value of $228.0M and an enterprise value of $207.7M.

  • Revenue in the twelve months to 30 June 2026: $73.8M. The latest quarter grew 11.6% year on year.

  • Net income over the same four quarters: $11.3M, a 15.3% net margin.

  • Diluted earnings per share, trailing twelve months: $1.31.

  • Free cash flow in the twelve months to 30 June 2026: $8.4M, after $1.3M of capital spending.

  • Electromed, Inc. spent $3.9M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 8.4M.

  • Trailing P/E: 21.0×; forward P/E: 44.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Electromed, Inc. employs 195 people — $378K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

ELMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ELMDElectromed, Inc.$228.0M
94
STIMNeuronetics, Inc.$230.9M
64
INFUInfuSystem Holdings, Inc.$242.0M
100
RXSTRxSight, Inc.$249.2M
51
LABStandard BioTools, Inc.$269.1M
35
TLSITriSalus Life Sciences, Inc.$279.0M
34
TMCITreace Medical Concepts, Inc.$287.4M
56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Electromed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ELMD news & analysis

Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event

Business Wire · 9 Sept 2026neutral

Electromed, Inc. announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference and the LD Micro 20th Annual Main Event. The company's participation in these investor conferences is part of its ongoing engagement with the investment community.

Why it matters — This announcement signals that ELMD will have opportunities to present and engage with investors at two upcoming industry conferences, which could increase visibility for the company.

Electromed: Contrarian 'Buy' With SmartVest

Seeking Alpha · 28 Aug 2026positive

Electromed's direct-to-patient model, broad payer coverage, and disciplined sales execution are cited as supporting durable SmartVest growth. The bronchiectasis market is described as substantially underpenetrated, offering a long runway for HFCWO adoption, while hospital revenue, though volatile, remains small and increased for the full year.

Why it matters — ELMD watchers would care because the item highlights durable SmartVest growth drivers and an underpenetrated market, while addressing the volatility of the hospital channel as a limited factor.

Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript

Seeking Alpha · 25 Aug 2026neutral

Seeking Alpha published the transcript of Electromed, Inc.'s Q4 2026 earnings call, based on the item's headline. The transcript covers the company's fourth-quarter earnings discussion for fiscal 2026.

Why it matters — ELMD watchers can review management's commentary from the Q4 2026 earnings call to understand the company's recent performance and outlook directly from its leadership.

Electromed, Inc. (ELMD) Surpasses Q4 Earnings Estimates

Zacks Investment Research · 25 Aug 2026positive

Electromed, Inc. reported quarterly earnings of $0.39 per share, surpassing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.25 per share in the same quarter a year ago.

Why it matters — The earnings beat marks an improvement over the prior-year quarter and exceeds analyst expectations, which is relevant to ELMD watchers tracking the company's financial performance.

Electromed Announces CEO's Planned Retirement

Business Wire · 25 Aug 2026neutral

Electromed, Inc. announced the planned retirement of its CEO, as reported by Business Wire from New Prague, Minnesota. The announcement signals an upcoming leadership transition at the company.

Why it matters — A CEO retirement is significant for ELMD watchers because it introduces a leadership transition that could affect the company's strategic direction.

FAQ

Frequently asked questions about ELMD stock

What is the ELMD stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Electromed, Inc. have a median 12-month price target of $49, with estimates ranging from $47 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELMD stock a buy right now?

Of the 2 analysts covering Electromed, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Electromed, Inc. 94 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELMD?

As at 12 Sept 2026, Electromed, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will ELMD stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +78.0% from the last close, and Ticker Nerd's factor model ranks Electromed, Inc. 94 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELMD stock forecast for 2030?

No analyst covering Electromed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $47 to $50 over the next 12 months.

How has ELMD stock performed over the past year?

Electromed, Inc. returned +8.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Electromed, Inc. do?

Electromed, Inc. is a medical device company focused on airway clearance therapy for patients with compromised pulmonary function.

What is the latest news on ELMD?

The most recent item we track (Business Wire, 9 Sept 2026): "Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event". Electromed, Inc. announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference and the LD Micro 20th Annual Main Event. The company's participation in these investor conferences is part of its ongoing engagement with the investment community.

Company

About Electromed, Inc.

Electromed, Inc. is a medical device company focused on airway clearance therapy for patients with compromised pulmonary function. The company develops, manufactures, markets, and sells the SmartVest airway clearance system and related products that use high frequency chest wall oscillation (HFCWO) to help mobilize airway secretions. Its portfolio includes home-use therapy systems as well as products designed for acute care settings, serving patients with conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular disorders. Electromed also offers connected therapy solutions that support communication between patients and physicians and help monitor treatment use. Headquartered in New Prague, Minnesota, Electromed plays a specialized role in respiratory care by providing noninvasive airway management tools used by clinicians, patients, and healthcare providers in the United States and selected international markets.

CEO Mr. James L. Cunniff · 195 employees · United States · https://smartvest.com